These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23673501)

  • 1. Circulating melanoma cells as a predictive biomarker.
    Karakousis G; Yang R; Xu X
    J Invest Dermatol; 2013 Jun; 133(6):1460-2. PubMed ID: 23673501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma.
    Khoja L; Lorigan P; Zhou C; Lancashire M; Booth J; Cummings J; Califano R; Clack G; Hughes A; Dive C
    J Invest Dermatol; 2013 Jun; 133(6):1582-90. PubMed ID: 23223143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment.
    Gray ES; Reid AL; Bowyer S; Calapre L; Siew K; Pearce R; Cowell L; Frank MH; Millward M; Ziman M
    J Invest Dermatol; 2015 Aug; 135(8):2040-2048. PubMed ID: 25830652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Number of Circulating Tumor Cells Predicts Poor Survival of Cutaneous Melanoma Patients in China.
    Li J; Fu W; Zhang W; Li P
    Med Sci Monit; 2018 Jan; 24():324-331. PubMed ID: 29337932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor Cells in Stage IV Melanoma Patients.
    Hall CS; Ross M; Bowman Bauldry JB; Upshaw J; Karhade MG; Royal R; Patel S; Lucci A
    J Am Coll Surg; 2018 Jul; 227(1):116-124. PubMed ID: 29746918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
    Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Tumor Cells and Early Relapse in Node-positive Melanoma.
    Lucci A; Hall CS; Patel SP; Narendran B; Bauldry JB; Royal RE; Karhade M; Upshaw JR; Wargo JA; Glitza IC; Wong MKK; Amaria RN; Tawbi HA; Diab A; Davies MA; Gershenwald JE; Lee JE; Hwu P; Ross MI
    Clin Cancer Res; 2020 Apr; 26(8):1886-1895. PubMed ID: 32015020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
    Zhou J; Dong F; Cui F; Xu R; Tang X
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor cells and melanoma progression.
    Xu X; Zhong JF
    J Invest Dermatol; 2010 Oct; 130(10):2349-51. PubMed ID: 20842140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future of circulating tumor cells in the melanoma clinical and research laboratory settings.
    De Souza LM; Robertson BM; Robertson GP
    Cancer Lett; 2017 Apr; 392():60-70. PubMed ID: 28163189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
    Koyanagi K; O'Day SJ; Gonzalez R; Lewis K; Robinson WA; Amatruda TT; Wang HJ; Elashoff RM; Takeuchi H; Umetani N; Hoon DS
    J Clin Oncol; 2005 Nov; 23(31):8057-64. PubMed ID: 16258104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
    BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma.
    Khoja L; Shenjere P; Hodgson C; Hodgetts J; Clack G; Hughes A; Lorigan P; Dive C
    Melanoma Res; 2014 Feb; 24(1):40-6. PubMed ID: 24201293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
    Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma.
    Klinac D; Gray ES; Freeman JB; Reid A; Bowyer S; Millward M; Ziman M
    BMC Cancer; 2014 Jun; 14():423. PubMed ID: 24915896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
    Salgia R; Weaver RW; McCleod M; Stille JR; Yan SB; Roberson S; Polzer J; Flynt A; Raddad E; Peek VL; Wijayawardana SR; Um SL; Gross S; Connelly MC; Morano C; Repollet M; Sanders R; Baeten K; D'Haese D; Spigel DR
    Invest New Drugs; 2017 Jun; 35(3):334-344. PubMed ID: 28299514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial.
    Riethdorf S; Müller V; Loibl S; Nekljudova V; Weber K; Huober J; Fehm T; Schrader I; Hilfrich J; Holms F; Tesch H; Schem C; von Minckwitz G; Untch M; Pantel K
    Clin Cancer Res; 2017 Sep; 23(18):5384-5393. PubMed ID: 28679772
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.
    Yang C; Zou K; Zheng L; Xiong B
    BMC Cancer; 2017 Nov; 17(1):725. PubMed ID: 29115932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.